Halozyme Therapeutics announced on January 28, 2026 that it had completed the acquisition of Surf Bio, Inc., a biopharmaceutical company that develops hyperconcentration technology for biologics. The deal, finalized in December 2025, is valued at up to $400 million, comprising an upfront payment of $300 million and up to $100 million in milestone payments. Surf Bio’s platform can concentrate biologics to 500 mg/mL, enabling single‑shot auto‑injector delivery and extending the life cycle of existing products.
The acquisition adds a second hyperconcentration technology to Halozyme’s portfolio, complementing its existing ENHANZE and Elektrofi platforms. By integrating Surf Bio’s capability, Halozyme can offer partners ultra‑high‑concentration formulations that reduce injection volume, improve patient adherence, and open new markets for both biologics and small molecules. The technology also positions the company to capture a broader royalty base as partners launch higher‑concentration products into the 2030s.
Halozyme raised its 2026 financial guidance in the same announcement. Total revenue is now projected at $1.71 billion to $1.81 billion, up 23%–30% from the prior guidance of $1.43 billion to $1.53 billion. Royalty revenue is expected to reach $1.13 billion to $1.17 billion, a 30%–35% increase over the previous range of $6.50 billion to $7.00 billion. Adjusted EBITDA guidance was lifted to $1.125 billion to $1.205 billion, and non‑GAAP diluted EPS is now forecast at $7.75 to $8.25, reflecting new investments of roughly $60 million in Hypercon and Surf Bio.
For 2025, Halozyme provided preliminary estimates of total revenue between $1.385 billion and $1.400 billion, up 36%–38% from the prior guidance of $1.3 billion to $1.375 billion. Royalty revenue for the year is projected at $865 million to $870 million, a 51%–52% jump over the previous estimate of $600 million to $620 million. Product sales are expected to reach $372 million to $377 million, while collaboration revenue is forecast at $148 million to $153 million.
Segment analysis shows that product sales and collaboration revenue are the primary drivers of the 2025 revenue increase, while the surge in royalty revenue reflects the expected rollout of Surf Bio‑enabled high‑concentration products. The company’s ENHANZE platform continues to generate steady royalty income, but the addition of Surf Bio is expected to accelerate the pace at which new partners launch higher‑concentration biologics, thereby expanding the royalty stream into the next decade.
Dr. Helen Torley, President and CEO, said the acquisition “adds a second innovative hyperconcentration technology that will accelerate new product launches and broaden our royalty base into the 2030s.” She added that the upgraded guidance “reflects confidence in the combined platforms and the strong demand from partners for single‑shot delivery solutions.”
Market reaction to the announcement was modest but positive. Shares edged 0.5% higher in Wednesday morning trading, and pre‑market activity showed a 0.19% lift. Analysts noted that the revenue guidance now exceeds consensus estimates of $1.69 billion, while the EPS guidance remains slightly below the analyst estimate of $8.21, a difference attributed to the $60 million investment in new technologies.
The guidance increase signals management’s belief that the Surf Bio platform will generate incremental revenue and royalty income, offsetting the upfront and milestone costs. The company’s robust cash position and ability to fund growth while returning capital to shareholders are highlighted as key strengths. Headwinds include the capital outlay for Hypercon and Surf Bio integration, but the expected tailwinds from accelerated product launches and expanded royalty streams are expected to outweigh these costs over the medium term.
Halozyme’s strategic focus on hyperconcentration technologies positions it to capture a growing market for high‑concentration biologics and single‑shot delivery. The acquisition and guidance upgrade reinforce the company’s long‑term growth trajectory, strengthen its cash flow generation, and expand its revenue mix beyond the core ENHANZE platform. The move is expected to enhance shareholder value by creating new revenue streams and improving the company’s competitive positioning in the drug‑delivery space.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.